Treatment of Early-Stage Non-Small Cell Lung Cancer

Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology
Credits Available: 4.50 AMA PRA Category 1 Credit™ & 4.50 MOC points

Immunotherapy, which has demonstrated benefits in advanced and metastatic settings, is moving into early non-small cell lung cancer treatment, expanding options for patients with resected or resectable early-stage non-small cell lung cancer. This rapid evolution of the early NSCLC treatment landscape, while exciting, has created clinical challenges as health care providers struggle with translating these clinical trial results into real-world clinical practices in the adjuvant and neoadjuvant settings. This educational initiative establishes impactful small group interactions among oncology care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with early-stage NSCLC.


CME/CE Accreditation Information

Itinerary

Part 1

Treatment of Early-Stage Non-Small Cell Lung Cancer - Baseline Assessment

The following questions are designed to assess your knowledge and practice of patients with early-stage non-small cell lung cancer.

Module 1: Neoadjuvant and Perioperative NSCLC Immunotherapy Trial Updates

This module will cover key trial updates for immunotherapies in the neoadjuvant or perioperative treatment of NSCLC.

Module 2: Adjuvant NSCLC Immunotherapy Trial Updates

This module will cover key trial updates for immunotherapies in the adjuvant treatment of NSCLC

Module 3: Recognition & Management of Immune-Related Adverse Events

This module will cover the recognition and management of immune-related adverse events from immunotherapies in the treatment of NSCLC.

Treatment of Early-Stage Non-Small Cell Lung Cancer - Final Assessment

The following questions are designed to assess your gained knowledge and practice of patients with early-stage non-small cell lung cancer.

Live Group Discussion 1

During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with early-stage NSCLC.

Part 2

Patient Case 1 - Margaret's Case

62 yo female with a new diagnosis of stage 3A NSCLC (mediastinal LN involvement). On treatment, develops irAE of pneumonitis.

Patient Case 2 - Terry's Case

68 yo male with a new diagnosis of stage 2A NSCLC (with no nodal involvement). Requires further consideration for neoadjuvant/perioperative vs. adjuvant therapy.

Your Action Plan In Early-Stage Non-Small Cell Lung Cancer

In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with Early-Stage Non-Small Cell Lung Cancer.

Live Group Discussion 2

During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.

Interested in becoming a Group Leader?

Requirements:
Experts in the management of patients with early-stage non-small cell lung cancer. Apply Now

Interested in participating in this curriculum? You can join one of the following groups:

Michelle Turner, MSN, CRNP
Nurse Practitioner Manager of Solid Tumor Oncology
Enroll